Jaguar Health (JAGX) Return on Capital Employed (2015 - 2026)
Jaguar Health (JAGX) posted quarterly Return on Capital Employed of 131.73% for Q1 2026, up 26393.0% year-over-year from N/an in Q1 2025, and down 60.06% quarter-over-quarter from 329.85% in Q4 2025.
Jaguar Health (JAGX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Return on Capital Employed for 12 consecutive years, with 131.73% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 26393.0% year-over-year to 131.73%; the TTM figure through Mar 2026 stood at 131.73% (up 26393.0% YoY), while the FY2025 annual figure was 384.44%, up 47963.0% from the prior year.
- Return on Capital Employed retreated to 131.73% in Q1 2026 per JAGX's latest filing, from 329.85% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 329.85% in Q4 2025 and bottomed at 257.48% in Q3 2025.
- Historically, Return on Capital Employed has averaged 88.82% across 5 years, with a median of 128.51% in 2022.
- On a YoY basis, Return on Capital Employed climbed as much as 41492 bps in 2025 and fell as far as 18207 bps in 2025.
- Jaguar Health's Return on Capital Employed stood at 180.84% in 2022, then soared by 44 bps to 100.61% in 2023, then climbed by 15 bps to 85.07% in 2024, then soared by 488 bps to 329.85% in 2025, then slumped by 60 bps to 131.73% in 2026.
- Business Quant data shows JAGX's Return on Capital Employed at 131.73% in Q1 2026, 329.85% in Q4 2025, and 257.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 131.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131.73% |
| Dec 31, 2025 | 329.85% |
| Sep 30, 2025 | -257.48% |
| Jun 30, 2025 | -159.10% |
| Mar 31, 2025 | -132.20% |
| Dec 31, 2024 | -85.07% |
| Sep 30, 2024 | -75.41% |
| Jun 30, 2024 | -80.82% |
| Mar 31, 2024 | -92.62% |
| Dec 31, 2023 | -100.61% |
| Sep 30, 2023 | -90.91% |
| Jun 30, 2023 | -133.60% |
| Mar 31, 2023 | -154.10% |
| Dec 31, 2022 | -180.84% |
| Sep 30, 2022 | -164.75% |
| Jun 30, 2022 | -135.41% |
| Mar 31, 2022 | -128.51% |
| Dec 31, 2021 | -99.77% |
| Sep 30, 2021 | -66.82% |
| Jun 30, 2021 | -54.69% |